Abstract:The identification of protective agents for the treatment of neurodegenerative diseases is the mainstay therapeutic goal to modify the disease course and arrest the irreversible disability progression. Pharmacological therapies synergistically targeting multiple pathogenic pathways, including oxidative stress, mitochondrial dysfunction, and inflammation, are prime candidates for neuroprotection. Combination or synergistic therapy with melatonin, whose decline correlates with altered sleep/wake cycle and impaired glymphatic "waste clearance" system in neurodegenerative diseases, has a great therapeutic potential to treat inflammatory neurodegenerative states. Despite the protective outcomes observed in preclinical studies, mild or poor outcomes were observed in clinical settings, suggesting that melatonin combinations promoting synergistic actions at appropriate doses might be more suitable to treat multifactorial neurodegenerative disorders. In this review, we first summarize the key melatonin actions and pathways contributing to cell protection and its therapeutic implication in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). We remark the major controversies in the field, mostly generated by the lack of a common consensus for the optimal dosing, molecular targets, and toxicity. Then, we review the literature investigating the efficacy of melatonin combinations with approved or investigational neuroprotective agents and of melatonin‐containing hybrid molecules, both in vitro and in animal models of AD, PD, and MS, as well as the efficacy of add‐on melatonin in clinical settings. We highlight the rationale for such melatonin combinations with a focus on the comparison with single‐agent treatment and on the assays in which an additive or a synergistic effect has been achieved. We conclude that a better characterization of the mechanisms underlying such melatonin synergistic actions under neuroinflammation at appropriate doses needs to be tackled to advance successful clinical translation of neuroprotective melatonin combination therapies or melatonin‐based hybrid molecules.

Role of melatonin in regulating neurogenesis: Implications for the neurodegenerative pathology and analogous therapeutics for Alzheimer’s disease

Melatonin regulates A production/clearance balance and A neurotoxicity: A potential therapeutic molecule for Alzheimer's disease

Melatonin: a multitasking indoleamine to modulate hippocampal neurogenesis

The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases

Melatonin: A potential nighttime guardian against Alzheimer's

Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin

Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer's disease neuropathology

Melatonin Inhibits Hypoxia-Induced Alzheimer's Disease Pathogenesis by Regulating the Amyloidogenic Pathway in Human Neuroblastoma Cells

The Vital Role of Melatonin and Its Metabolites in the Neuroprotection and Retardation of Brain Aging

Neuroinflammation and Neurogenesis in Alzheimer’s Disease and Potential Therapeutic Approaches

Melatonin protects against amyloid-β-induced impairments of hippocampal LTP and spatial learning in rats

Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells

Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases

The intricate interplay between microglia and adult neurogenesis in Alzheimer's disease

Melatonin Augments the Expression of Core Transcription Factors in Aged and Alzheimer's Patient Skin Fibroblasts

The Protective Effects of Melatonin on Neural Degenerative Disease and Postoperative Cognitive Dysfunction

Effects of Melatonin and Its Analogues on Neural Stem Cells.

Melatonin attenuates methamphetamine-induced inhibition of neurogenesis in the adult mouse hippocampus: An in vivo study

Protective Effect of the Novel Melatonin Analogue Containing Donepezil Fragment on Memory Impairment via MT/ERK/CREB Signaling in the Hippocampus in a Rat Model of Pinealectomy and Subsequent Aβ1-42 Infusion